Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies

por Olive, Jessica F., Qin, Yuanbo, DeCristo, Molly J., Laszewski, Tyler, Greathouse, Frances, McAllister, Sandra S.
Publicado 2018

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

por Ubellacker, Jessalyn M., Haider, Marie-Therese, DeCristo, Molly J., Allocca, Gloria, Brown, Nicola J., Silver, Daniel P., Holen, Ingunn, McAllister, Sandra S.
Publicado 2017

CDK4/6 inhibition triggers anti-tumor immunity

por Goel, Shom, DeCristo, Molly J., Watt, April C., BrinJones, Haley, Sceneay, Jaclyn, Li, Ben B., Khan, Naveed, Ubellacker, Jessalyn M., Xie, Shaozhen, Metzger-Filho, Otto, Hoog, Jeremy, Ellis, Matthew J., Ma, Cynthia, Ramm, Susanne, Krop, Ian E., Winer, Eric P., Roberts, Thomas M., Kim, Hye-Jung, McAllister, Sandra S., Zhao, Jean J.
Publicado 2017